Handling Multi-Language Labelling and Patient Information Leaflets (PILs) in the EU
In the increasingly globalized pharmaceutical market, effective communication with patients and healthcare professionals is paramount. In the European Union (EU), pharmaceutical companies must navigate a complex landscape of regulations governing labelling, particularly concerning multi-language requirements for Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PILs). This regulatory explainer manual aims to provide regulatory affairs teams with a detailed understanding of the requirements and process involved in ensuring product compliance. It focuses on the expectations of regulatory authorities such as the European Medicines Agency (EMA) and Member States, and outlines best practices for adherence to the guidelines.
Context
Regulatory Affairs (RA) professionals play a crucial role in ensuring that pharmaceutical products are marketed in compliance with legislation, which is particularly challenging in multilingual markets like the EU. Labelling serves as a key communication tool that informs users about the product’s purpose, proper use, and safety information. The legal framework for labelling in the EU is predominantly covered by:
- Directive 2001/83/EC on the Community code relating to medicinal products for human use
- Regulation (EU) No 1169/2011 on the provision of food information to consumers
- Regulation
In addition, the International Council for Harmonisation (ICH) guidelines provide recommendations that should be considered during the preparation of labelling documentation for global markets, including the EU.
Legal/Regulatory Basis
The European regulatory framework mandates specific requirements regarding labelling and PILs. Key elements include:
- Language Requirements: According to Article 65 of Directive 2001/83/EC, labelling must be provided in the official language(s) of the Member State in which the product is sold.
- Summary of Product Characteristics (SmPC): The SmPC serves as the basis for healthcare professionals and must include comprehensive information regarding the product’s usage, indications, contraindications, and adverse effects.
- Patient Information Leaflet (PIL): The PIL is designed for patients and must be clear and understandable, summarizing key information derived from the SmPC.
The EMA and other national authorities have issued detailed guidelines regarding the content and format of SmPCs and PILs. These include the QRD (Quality Review Document) templates that facilitate consistency and compliance across Member States.
Documentation
To comply with regulatory requirements, specific documentation must be prepared for multi-language labelling. The following components are critical:
1. Summary of Product Characteristics (SmPC)
The SmPC should present a complete and accurate summary of the product. It must adhere to the specific structure outlined in the Commission Guideline on the SmPC (CPMP/463/00). Consideration should be given to the following sections:
- Therapeutic indications: Clear statements of what the product is intended to treat.
- Dosage and administration: Detailed instructions on how the product should be used.
- Contraindications: Any conditions under which the product should not be used.
- Adverse reactions: A comprehensive list of potential side effects.
2. Patient Information Leaflet (PIL)
The PIL must be designed and formatted according to the relevant provisions of Article 59 of Directive 2001/83/EC. It shall contain information easily understandable by the general public. The key aspects to cover in the PIL include:
- What the medicine is and what it is used for;
- Before you take this medicine;
- How to take this medicine;
- Possible side effects;
- How to store this medicine;
- Contents of the pack and other information.
3. QRD Templates
Utilization of the QRD templates for preparing SmPCs and PILs is highly recommended. These templates are accessible through the EMA website, ensuring compliance with the standardized format required by EU regulations. The registration process for documents usually requires submission of the QRD-compliant documents in the applicable languages.
Review/Approval Flow
Understanding the review and approval flow is pivotal for efficient regulatory submissions. Below is an overview of the critical steps in the approval process for multi-language labelling.
1. Initial Preparation
Before submission, it is essential to prepare the draft SmPC and PIL using the relevant QRD Templates and in all required languages. Collaboration between regulatory affairs and language experts is crucial to ensure translations maintain accuracy and adherence to regulatory terminology.
2. Internal Review
Once the documents are drafted, they should undergo an internal review involving cross-functional teams (CMC, Clinical, PV, QA). This step is vital to assess compliance with regulatory requirements and internal policies.
3. Submission to Regulatory Authorities
Submissions should be carried out through the appropriate electronic platform (e.g., eCTD submissions) where applicable, which is a requirement of the EMA and many Member States. Ensure that all documentation, including the original language documents and their respective translations, are included.
4. Assessment by the Regulatory Authority
The regulatory authority will assess submissions for compliance with applicable regulations. The timeline for assessment may vary by Member State. If deficiencies are identified, the authority will issue questions and request clarifications or additional information.
5. Final Approval and Publication
Upon successful resolution of queries, regulatory authorities grant approval, allowing for the marketing of the product. This is followed by the publication of approved product information on official platforms.
Common Deficiencies
To minimize the risk of delays during the review process, it is important to be aware of common deficiencies that may arise during submissions of multi-language labelling:
1. Inaccurate Translations
One of the most prevalent issues encountered is improper translations that deviate from the original text’s intent or lack adherence to regulatory terminology. Employing professional translators with experience in pharmaceutical language is essential.
2. Non-compliance with QRD Templates
Failure to use the QRD templates correctly or deviations from standard format requirements may lead to rejection. Ensure that all sections are completed and formatted accordingly.
3. Lack of Justification for Changes
If modifications are made to previously approved documents, robust justification must be provided to regulatory authorities. This includes explaining why changes were made and how they comply with current regulations. For instance, distinguishing whether a submission is a variation or a new application is crucial.
4. Missing Documentation
Incomplete submissions can result in significant delays. Verify that all necessary supporting documents are provided, including evidence of compliance with local regulations, evidence of expert reviews, and any consultation feedback.
RA-Specific Decision Points
Regulatory affairs professionals often encounter pivotal decision points that impact the submission process for multi-language labelling. Understanding when to apply specific strategies can advance product compliance effectively.
Variation vs New Application
Determining whether to file a variation or a new application hinges on the extent of changes being made. If a change to the SmPC requires updates to the PIL and labelling that do not alter the core indications, a variation is appropriate. In contrast, significant changes in formulation or new indications necessitate a new application. Justifying the chosen route during submission is critical for regulatory compliance.
Bridging Data
When presenting bridging data, particularly for multi-language labelling, it is vital to establish a clear rationale for how the data supports the change being proposed. Regulatory authorities are concerned with the consistency of product information across different languages. Presenting robust scientific evidence that supports any updates or changes strengthens your submission.
Engagement with Regulatory Authorities
Proactive engagement with regulatory authorities during the early stages can facilitate better understanding and resolution of potential issues. Prior to submission, obtaining feedback on labelling drafts can avert common pitfalls and likely deficiencies.
Conclusion
Effective management of multi-language labelling and PILs in the EU regulatory landscape presents challenges but also opportunities for innovation in communication with patients and healthcare providers. By adhering to established regulations and guidelines, collaborating with cross-functional teams, and maintaining vigilance at critical decision points, regulatory affairs professionals can ensure compliance and minimize the risk of deficiencies during the review process. As the industry continues to evolve, staying informed about changes in regulations and expectations is essential for success.